Future studies should be conducted to investigate a possible implication of iNOS variants in the risk of suffering from pancreatic cancer and the use of both eNOS and iNOS as therapeutic targets in patients with high expressions of these components. This evidence concerns the gene NOS2 and familial pancreatic carcinoma.